Banque Transatlantique’s Neurocrine Biosciences NBIX Stock Holding History

Banque Transatlantique’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3K	Buy	+150	New	+$22.3K	﹤0.01%	399

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Banque Transatlantique's NBIX Position: Q2 2026 in Review

Banque Transatlantique opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 150 shares worth $25.3K. The stake represents ﹤0.01% of the portfolio and ranks #399 among its holdings.

260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Banque Transatlantique held 150 shares of Neurocrine Biosciences worth $25.3K as of Q2 2026.
Neurocrine Biosciences was a new Banque Transatlantique position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Banque Transatlantique's portfolio in Q2 2026, its #399 holding.
260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.